Related Experiment Video
Updated: Oct 12, 2025

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
Published on: September 14, 2010
Epidemiology of Kaposi's Sarcoma
Sophie Grabar1, Dominique Costagliola2
1Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP) and Assistance Publique-Hôpitaux de Paris (AP-HP), Unit of Public Health, St Antoine Hospital, 75001 Paris, France.
Kaposi's sarcoma (KS) incidence decreased in patients with HIV due to antiretroviral therapy. However, KS remains a significant cancer risk for people living with HIV (PLHIV), especially in certain populations and regions.
Area of Science:
- Oncology
- Virology
- Epidemiology
Background:
- Kaposi's sarcoma (KS) is an angioproliferative tumor linked to human herpesvirus 8 (HHV-8) and immunodeficiency.
- Antiretroviral therapy has significantly reduced KS incidence in people living with HIV (PLHIV) by restoring immunity.
- Despite treatment advances, KS remains a prevalent cancer among PLHIV, particularly in specific demographics and endemic regions.
Purpose of the Study:
- To review the current epidemiological landscape of Kaposi's sarcoma in the context of HIV infection.
- To highlight the persistent risk of KS in PLHIV even with improved immune function.
- To emphasize the importance of early access to care alongside antiretroviral treatment for KS risk reduction.
Main Methods:
- This review synthesizes recent epidemiological data on Kaposi's sarcoma.
- It analyzes trends in KS incidence among people living with HIV (PLHIV).
- The review considers the impact of antiretroviral therapy and immune status on KS development.
Main Results:
- Antiretroviral combinations have led to a dramatic decrease in KS incidence among PLHIV.
- KS continues to be a frequent cancer in PLHIV, with higher prevalence in men who have sex with men and sub-Saharan Africa.
- The risk of KS remains over 30 times higher in PLHIV compared to the general population, even with restored immunity.
Conclusions:
- Early initiation of antiretroviral treatment is crucial for reducing KS risk in PLHIV.
- Early access to healthcare services is essential to complement antiretroviral therapy.
- Ongoing surveillance and targeted interventions are necessary to further mitigate KS burden in PLHIV.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Retrovirus Life Cycles
Sexually Transmitted Infections

